Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 13Multiple Myeloma 6Thyroid Neoplasms 5Lymphoma 5Hematologic Neoplasms 5Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Carcinoma, Anaplastic 3Prostatic Neoplasms 3Brain Neoplasms 3Thyroid Cancer, Papillary 2Pancreatic Neoplasms 2Neurofibromatosis 1 2Neoplasm Metastasis 2Lung Neoplasms 2Adenocarcinoma, Follicular 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Stomach Neoplasms 1Solid Tumors, KRAS Mutation; SOS1 1Rectal Neoplasms 1Ovarian Neoplasms 1Neurofibroma, Plexiform 1Leukemia, Myelomonocytic, Juvenile 1Glioblastoma 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × EGFR-mutant Non-small Cell Lung Cancer × trametinib × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡